BCR-complex-specific antibodies and methods of using same
AssigneeMacroGenics, Inc.
InventorsLeslie S. Johnson, Ling Huang
Life of this patent
Estimating the term…
Abstract
This invention relates to chimeric and humanized antibodies that specifically bind the BCR complex, and particularly chimeric and humanized antibodies to the BCR complex. The invention also relates to methods of using the antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease.
Claims15
A method of treating an autoimmune or immune-mediated inflammatory disease in a subject, comprising administering to said subject a therapeutically effective amount of a diabody that binds human BCR complex, wherein said diabody comprises:
- (I) an amino acid sequence of an immunoglobulin light chain variable region (VL) that is a humanized variant of BCC VL that comprises:
- (A) a modification at Kabat residue 37;
- (B) a modification at Kabat residue 45;
- or
- (C) both (A) and (B);
- and
- (II) an amino acid sequence of an immunoglobulin heavy chain variable region (VH) that is a humanized variant of BCC VH that comprises a modification of one or more of Kabat residues 48, 62, 66, 67, 68, 69, 70, 71 or 73.
Dependencies are inferred from the claim text.